請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50156
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李心予(Hsinyu Lee) | |
dc.contributor.author | Yin-Chieh Chien | en |
dc.contributor.author | 簡吟潔 | zh_TW |
dc.date.accessioned | 2021-06-15T12:31:08Z | - |
dc.date.available | 2018-08-24 | |
dc.date.copyright | 2016-08-24 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-04 | |
dc.identifier.citation | 1 Marek Michalak, E. F. C., Nasrin Mesaeli, Kimitoshi Nakamura and Michal Opas. Calreticulin , one protein, one gene, many functions. Biochem. J., 12 (1999).
2 Martin, V. et al. Identification by mutational analysis of amino acid residues essential in the chaperone function of calreticulin. The Journal of biological chemistry 281, 2338-2346, doi:10.1074/jbc.M508302200 (2006). 3 M. Michalak, J. M. R. P., M. Opas. Ca2+ signaling and calcium binding chaperones of the endoplasmic reticulum. Cell calcium, 10, doi:10.1016/s0143-4160(02)00188-4 (2002). 4 Marek Michalak, R. E. M., Kimberly Burns and Michal Opas. Calreticulin. Biochem. J., 12 (1992). 5 Andrew J. Crofts, a. N. L.-C., a,1 Michela Pesca, b Alessandro Vitale, b and & Denecke, J. BiP and Calreticulin Form an Abundant Complex That Is Independent of Endoplasmic Reticulum Stress. The Plant Cell,, 11 (1998). 6 Araki, K. & Nagata, K. Protein folding and quality control in the ER. Cold Spring Harbor perspectives in biology 3, a007526, doi:10.1101/cshperspect.a007526 (2011). 7 Michalak, M., Groenendyk, J., Szabo, E., Gold, L. I. & Opas, M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. The Biochemical journal 417, 651-666, doi:10.1042/BJ20081847 (2009). 8 Ireland, B. S., Brockmeier, U., Howe, C. M., Elliott, T. & Williams, D. B. Lectin-deficient calreticulin retains full functionality as a chaperone for class I histocompatibility molecules. Molecular biology of the cell 19, 2413-2423, doi:10.1091/mbc.E07-10-1055 (2008). 9 Michalak, S. B. a. M. Expression of Calreticulin in Escherichia coli and Identification of Its Ca2+ Binding Domains. THE JOURNAL OF BIOLOGICAL CHEMISTRY, 8 (1991). 10 Lu, Y. C. et al. Changes in tumor growth and metastatic capacities of J82 human bladder cancer cells suppressed by down-regulation of calreticulin expression. The American journal of pathology 179, 1425-1433, doi:10.1016/j.ajpath.2011.05.015 (2011). 11 Chen, C. N. et al. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Annals of surgical oncology 16, 524-533, doi:10.1245/s10434-008-0243-1 (2009). 12 Orr, A. W. et al. Low density lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly. The Journal of cell biology 161, 1179-1189, doi:10.1083/jcb.200302069 (2003). 13 Kimitoshi Nakamura, E. B.-W., , Kimberly Burns,, Marc P. Fadel,, Mira Lozyk,, Ing Swie Goping,, Michal Opas, R. Chris Bleackley, Douglas R. Green, and Marek Michalak. Changes in Endoplasmic Reticulum Luminal Environment Affect Cell Sensitivity to Apoptosis. The Journal of cell biology, 10 (2000). 14 Lu, Y. C., Weng, W. C. & Lee, H. Functional Roles of Calreticulin in Cancer Biology. BioMed research international 2015, 526524, doi:10.1155/2015/526524 (2015). 15 Yang, F. M., Feng, S. J., Lai, T. C. & Hu, M. C. A calreticulin-dependent nuclear export signal is involved in the regulation of liver receptor homologue-1 protein folding. The Biochemical journal 471, 199-209, doi:10.1042/BJ20150252 (2015). 16 Chao, M. P. et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Science translational medicine 2, 63ra94, doi:10.1126/scitranslmed.3001375 (2010). 17 Wiersma, V. R., Michalak, M., Abdullah, T. M., Bremer, E. & Eggleton, P. Mechanisms of Translocation of ER Chaperones to the Cell Surface and Immunomodulatory Roles in Cancer and Autoimmunity. Frontiers in oncology 5, 7, doi:10.3389/fonc.2015.00007 (2015). 18 Gold, L. I. et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 24, 665-683, doi:10.1096/fj.09-145482 (2010). 19 Zamanian, M., Veerakumarasivam, A., Abdullah, S. & Rosli, R. Calreticulin and cancer. Pathology oncology research : POR 19, 149-154, doi:10.1007/s12253-012-9600-2 (2013). 20 Hsu, W. M. et al. Calreticulin expression in neuroblastoma--a novel independent prognostic factor. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 16, 314-321, doi:10.1093/annonc/mdi062 (2005). 21 Kageyama, S. et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clinical chemistry 50, 857-866, doi:10.1373/clinchem.2003.027425 (2004). 22 Shu, Q., Li, W., Li, H. & Sun, G. Vasostatin inhibits VEGF-induced endothelial cell proliferation, tube formation and induces cell apoptosis under oxygen deprivation. International journal of molecular sciences 15, 6019-6030, doi:10.3390/ijms15046019 (2014). 23 Petrova, M. J. K. a. T. V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene, 8 (2000). 24 Hicklin, D. J. E., L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23, 1011-1027, doi:10.1200/JCO.2005.06.081 (2005). 25 Marlene Meyer, M. C. et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. The EMBO Journal, 12 (1999). 26 Holmes, K., Roberts, O. L., Thomas, A. M. & Cross, M. J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cellular signalling 19, 2003-2012, doi:10.1016/j.cellsig.2007.05.013 (2007). 27 Frickel, E. M. et al. TROSY-NMR reveals interaction between ERp57 and the tip of the calreticulin P-domain. Proceedings of the National Academy of Sciences of the United States of America 99, 1954-1959, doi:10.1073/pnas.042699099 (2002). 28 Nishi K. Singh, C. D. A., and Hira L. Nakhasi. Identification of calreticulin as a rubella virus RNA binding protein. Proc. Natl. Acad. Sci. USA, 5 (1994). 29 Lwin, Z. M. et al. Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 23, 1559-1566, doi:10.1038/modpathol.2010.173 (2010). 30 Sheng, W. et al. Overexpression of calreticulin contributes to the development and progression of pancreatic cancer. Journal of cellular physiology 229, 887-897, doi:10.1002/jcp.24519 (2014). 31 Du, X. L. et al. Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. Journal of molecular medicine 85, 863-875, doi:10.1007/s00109-007-0159-4 (2007). 32 Eric, A. et al. Effects of humoral immunity and calreticulin overexpression on postoperative course in breast cancer. Pathology oncology research : POR 15, 89-90, doi:10.1007/s12253-008-9112-2 (2009). 33 Goel, H. L. & Mercurio, A. M. VEGF targets the tumour cell. Nature reviews. Cancer 13, 871-882, doi:10.1038/nrc3627 (2013). 34 Cao, Y. et al. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer research 72, 3912-3918, doi:10.1158/0008-5472.CAN-11-4058 (2012). 35 Perrot-Applanat, M. & Di Benedetto, M. Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion. Cell adhesion & migration 6, 547-553, doi:10.4161/cam.23332 (2012). 36 Fan, F. et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24, 2647-2653, doi:10.1038/sj.onc.1208246 (2005). 37 Robin E. Bachelder, A. C., 2 Jun Chung, Melissa A. Wendt, Leslie M. Shaw, Gregory Robinson,3 and & Mercurio4, A. M. Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells1. Cancer research, 6 (2001). 38 Feng, R. et al. Calreticulin down-regulation inhibits the cell growth, invasion and cell cycle progression of human hepatocellular carcinoma cells. Diagnostic pathology 10, 149, doi:10.1186/s13000-015-0382-1 (2015). 39 Donnini, S., Ziche, M. & Morbidelli, L. Molecular Mechanisms of VEGF-Induced Angiogenesis. 19-25, doi:10.1007/978-1-4419-9148-5_3 (2004). 40 Ian Zachary*, G. G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovascular Research, 14 (2001). 41 Beck, B. et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478, 399-403, doi:10.1038/nature10525 (2011). 42 Fernandez-Zapico, M. E. GLI1 regulates a novel neuropilin-2/a6b1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO molecular medicine 5, 483-485, doi:10.1002/emmm.201302505 (2013). 43 Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature reviews. Cancer 8, 579-591, doi:10.1038/nrc2403 (2008). 44 Lee, J., Lee, J., Yu, H., Choi, K. & Choi, C. Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer letters 309, 145-150, doi:10.1016/j.canlet.2011.05.026 (2011). 45 Lee, J. et al. Blockade of VEGF-A suppresses tumor growth via inhibition of autocrine signaling through FAK and AKT. Cancer letters 318, 221-225, doi:10.1016/j.canlet.2011.12.014 (2012). 46 Shyu, C.-Y. A. C. a. A.-B. AU-rich elements-characterization and importance in mRNA degradation. TIBS, 6 (1995). 47 Jayita Guhaniyogi, G. B. Regulation of mRNA stability in mammalian cells. Gene, 13 (2001). 48 Khabar, K. S. Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements. Cellular and molecular life sciences : CMLS 67, 2937-2955, doi:10.1007/s00018-010-0383-x (2010). 49 Griseri, P. & Pages, G. Control of pro-angiogenic cytokine mRNA half-life in cancer: the role of AU-rich elements and associated proteins. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 34, 242-254, doi:10.1089/jir.2013.0140 (2014). 50 Sheila S.-Y.Peng, C.-Y. A. C. & Shyu, N. X. a. A.-B. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. The EMBO Journal, 10 (1998). 51 Kang, S. et al. TGF-beta Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells. Cancer research and treatment : official journal of Korean Cancer Association 47, 101-109, doi:10.4143/crt.2013.192 (2015). 52 Georg Nickenig, F. M., * Cornelius Müller, Anja Berger, Thomas Vogel, & Agapios Sachinidis, H. V., Michael Böhm. Destabilization of AT1 Receptor mRNA by Calreticulin. Circ Res., 7 (2002). 53 Yokoyama, M. & Hirata, K. New function of calreticulin: calreticulin-dependent mRNA destabilization. Circulation research 97, 961-963, doi:10.1161/01.RES.0000193564.46466.2a (2005). 54 Misquitta, C. M., Chen, T. & Grover, A. K. Control of protein expression through mRNA stability in calcium signalling. Cell calcium 40, 329-346, doi:10.1016/j.ceca.2006.04.004 (2006). 55 Totary-Jain, H. et al. Calreticulin destabilizes glucose transporter-1 mRNA in vascular endothelial and smooth muscle cells under high-glucose conditions. Circulation research 97, 1001-1008, doi:10.1161/01.RES.0000189260.46084.e5 (2005). 56 Xin, H. et al. Association of the von Hippel–Lindau Protein with AUF1 and Posttranscriptional Regulation of VEGFA mRNA. Molecular cancer research : MCR 10, 108-120, doi:10.1158/1541-7786.MCR-11-0435 (2012). 57 Arcondeguy, T., Lacazette, E., Millevoi, S., Prats, H. & Touriol, C. VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic acids research 41, 7997-8010, doi:10.1093/nar/gkt539 (2013). 58 Claffey, S.-C. S. a. K. P. Regulation of Human Vascular Endothelial Growth Factor mRNA Stability in Hypoxia by Heterogeneous Nuclear Ribonucleoprotein L. The Journal of biological chemistry, 8 (1999). 59 Peter S Yoo, A. L. M., Charles H Cha. Post-transcriptional regulation of vascular endothelial growth factor: Implications for tumor angiogenesis. World J Gastroenterol, 6 (2006). 60 Zhou, S., Gu, L., He, J., Zhang, H. & Zhou, M. MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia. Molecular and cellular biology 31, 4928-4937, doi:10.1128/MCB.06085-11 (2011). 61 Ma, S., Musa, T. & Bag, J. Reduced stability of mitogen-activated protein kinase kinase-2 mRNA and phosphorylation of poly(A)-binding protein (PABP) in cells overexpressing PABP. The Journal of biological chemistry 281, 3145-3156, doi:10.1074/jbc.M508937200 (2006). 62 Gray, B. G. a. N. K. The roles of cytoplasmic poly(A)-binding proteins in regulating gene expression: A developmental perspective. BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS., 17 (2004). 63 Michalak, K.-H. K. a. M. Calreticulin. Cell, 5 (1997). 64 Steven Johnson, M. M., Michal Opas and Paul Eggleton. The ins and outs of calreticulin: from the ER lumen to the extracellular space. TRENDS in Cell Biology, 8 (2001). 65 Lu, Y. C. et al. Calreticulin activates beta1 integrin via fucosylation by fucosyltransferase 1 in J82 human bladder cancer cells. The Biochemical journal 460, 69-78, doi:10.1042/BJ20131424 (2014). 66 Gray, L. C., Hughes, T. R. & van den Berg, C. W. Binding of human antigen R (HuR) to an AU-rich element (ARE) in the 3'untranslated region (3'UTR) reduces the expression of decay accelerating factor (DAF). Molecular immunology 47, 2545-2551, doi:10.1016/j.molimm.2010.07.002 (2010). 67 Lee, H. H. et al. Tristetraprolin suppresses AHRR expression through mRNA destabilization. FEBS letters 587, 1518-1523, doi:10.1016/j.febslet.2013.03.031 (2013). 68 Nanney, L. B. et al. Calreticulin enhances porcine wound repair by diverse biological effects. The American journal of pathology 173, 610-630, doi:10.2353/ajpath.2008.071027 (2008). 69 Barreau, C., Paillard, L. & Osborne, H. B. AU-rich elements and associated factors: are there unifying principles? Nucleic acids research 33, 7138-7150, doi:10.1093/nar/gki1012 (2005). 70 James M. Holaska, B. E. B., Dona C. Love, John A. Hanover, John Leszyk, and Bryce M. Paschal. Calreticulin Is a Receptor for Nuclear Export. The Journal of Cell Biology,, 14 (2001). 71 Kishor, A. et al. Hsp70 is a novel posttranscriptional regulator of gene expression that binds and stabilizes selected mRNAs containing AU-rich elements. Molecular and cellular biology 33, 71-84, doi:10.1128/MCB.01275-12 (2013). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50156 | - |
dc.description.abstract | 鈣網蛋白 (Calreticulin, CRT)是一個主要位於內質網的多功能伴護蛋白 (Chaperone protein)。之前有研究指出,在不同的癌症組織切片中,皆發現CRT會大量表現;另外也發現在膀胱癌J82細胞株中,CRT會透過穩定FUT1的mRNA,進而促進腫瘤的生成以及轉移。此外,大量表現CRT亦會增加在不同的癌症模式中被廣泛認為是血管新生主要調控者的血管內皮生長因子A的表現。在本研究中,我們嘗試在膀胱癌J82細胞株、胃癌AGS細胞株和前列腺癌PC3細胞株之癌症模式中,釐清CRT是否調控VEGF-A的mRNA 穩定性。我們發現,當減少CRT的表現後,VEGF-A的mRNA半衰期會明顯地縮短,進而抑制VEGF-A的mRNA以及蛋白質的表現。我們進一步的利用雙冷光試驗(dual-luciferase assay)證實CRT是透過辨認位於VEGF-A的3端為轉譯區 (3’ untranslated region, 3’UTR) 上之ARE片段(AU-rich element) 去調控VEGF-A的mRNA穩定性。確實,在生物素沉澱實驗 (biotin pull-down assay) 和液相層析串聯式質譜儀 (LC-MS/MS) 的結果中,證實CRT會與VEGF-A的ARE片段結合形成RNA-蛋白質複合體。綜合以上結果,本研究提供了一個全新的假說,在不同的癌症模式中,CRT會透過與位於VEGF-A的3端為轉譯區上之ARE片段結合而穩定VEGF-A的mRNA,而進一步促進癌症的進程以及有利於轉移之內皮細胞的血管新生。 | zh_TW |
dc.description.abstract | Calreticulin (CRT) is a multifunctional chaperone protein, which mainly locates on the membrane of endoplasmic reticulum (ER). Previous studies suggested that expression of CRT is up-regulated in various types of cancers and promotes tumorigenesis and metastasis through stabilizing fucosyltransferase 1 (FUT-1) mRNA in bladder cancer cell line J82. Besides, overexpressed CRT up-regulates the expression of Vascular Endothelial Growth Factor A (VEGF-A), which is widely considered as a major regulator for angiogenesis in different cancer models. In this study, we therefore attempt to clarify whether CRT regulates VEGF-A mRNA stability. We observed that depletion of CRT results in a significant decrease of mRNA stability of VEGF-A following by suppression of both VEGF-A RNA and protein levels in bladder cancer, gastric cancer, and prostate cancer. Further, dual luciferase assay was performed to demonstrate that CRT recognized AU-Rich Element (ARE) of VEGF-A in the 3’UTR to regulate stability of VEGF-A mRNA. Indeed, the results of biotin pull-down assay showed that CRT combines to ARE region of VEGF-A to form RNA-protein complex which was confirmed by additional liquid chromatography–mass spectrometry (LC-MS/MS). In conclusion, this study provides a novel machanism that CRT forms mRNA-protein complex with ARE at the 3’UTR of VEGF-A to increase VEGF-A mRNA stability in distinct cancer cell lines, which CRT enhances cancer progression and endothelial cells angiogenesis for metastasis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T12:31:08Z (GMT). No. of bitstreams: 1 ntu-105-R03b21020-1.pdf: 1949367 bytes, checksum: ec9f7f0af99e95afb28e21142619b886 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員審定書
致謝.................................................................I 中文摘要............................................................II Abstract............................................................III Content ..............................................................V List of tables........................................................VII List of figures.......................................................VIII Introduction...........................................................1 1.Calreticulin ........................................................1 1.1 Structure and biological functions of calreticulin .......................1 1.2 Calreticulin in cancer.............................................2 2. Vascular endothelial growth factors family ...............................3 2.1 Functions of vascular endothelial growth factors .......................3 2.2 VEGF-A in cancer cells ...........................................4 3. RNA stability ......................................................6 3.1 Significance and regulation of mRNA Stability ........................6 3.2 CRT and mRNA stability ..........................................7 3.3 Regulation of VEGF-A mRNA stability ..............................7 Rationale .............................................................9 Materials and methods ................................................10 Results ..............................................................16 Discussion ...........................................................21 Reference ...........................................................26 Figures .............................................................38 | |
dc.language.iso | en | |
dc.title | 鈣網蛋白調控血管內皮生長因子之mRNA穩定性 | zh_TW |
dc.title | Calreticulin regulates mRNA stability of Vascular Endothelial Growth Factor-A | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 朱家瑩,黃元勵,翁妏謹 | |
dc.subject.keyword | 鈣網蛋白,血管內皮生長因子A,AU-rich domain,RNA穩定性, | zh_TW |
dc.subject.keyword | Calreticulin,Vascular endothelial growth factor A,AU-rich domain,RNA stability, | en |
dc.relation.page | 54 | |
dc.identifier.doi | 10.6342/NTU201601928 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-04 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生命科學系 | zh_TW |
顯示於系所單位: | 生命科學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 1.9 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。